Your Good Partner in Biology Research

重組蛋白

產(chǎn)品名稱 貨號(hào) 規(guī)格
Recombinant Neisseria meningitidis serogroup C / serotype 2a Phosphopantetheine adenylyltransferase (coaD) CSB-YP375929NEX
CSB-EP375929NEX
CSB-BP375929NEX
CSB-MP375929NEX
CSB-EP375929NEX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Neisseria meningitidis serogroup C / serotype 2a 30S ribosomal protein S9 (rpsI) CSB-YP375930NEX
CSB-EP375930NEX
CSB-BP375930NEX
CSB-MP375930NEX
CSB-EP375930NEX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Neisseria meningitidis serogroup C / serotype 2a Protein slyX homolog (slyX) CSB-YP375931NEX
CSB-EP375931NEX
CSB-BP375931NEX
CSB-MP375931NEX
CSB-EP375931NEX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Neisseria meningitidis serogroup C / serotype 2a UPF0102 protein NMC2069 (NMC2069) CSB-YP375932NEX
CSB-EP375932NEX
CSB-BP375932NEX
CSB-MP375932NEX
CSB-EP375932NEX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Neisseria meningitidis serogroup C / serotype 2a Uridylate kinase (pyrH) CSB-YP375933NEX
CSB-EP375933NEX
CSB-BP375933NEX
CSB-MP375933NEX
CSB-EP375933NEX-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Human Uncharacterized protein C20orf202 (C20orf202) CSB-YP375934HU
CSB-EP375934HU
CSB-BP375934HU
CSB-MP375934HU
CSB-EP375934HU-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Human Immunoglobulin superfamily member 23 (IGSF23), partial CSB-YP375935HU1
CSB-EP375935HU1
CSB-BP375935HU1
CSB-MP375935HU1
CSB-EP375935HU1-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Xenopus tropicalis PAB-dependent poly (A)-specific ribonuclease subunit 3, partial CSB-YP375936XBF
CSB-EP375936XBF
CSB-BP375936XBF
CSB-MP375936XBF
CSB-EP375936XBF-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Danio rerio Phosphatidylinositide phosphatase SAC1-A (sacm1la), partial CSB-YP375937DIL1
CSB-EP375937DIL1
CSB-BP375937DIL1
CSB-MP375937DIL1
CSB-EP375937DIL1-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Danio rerio 2-oxo-4-hydroxy-4-carboxy-5-ureidoimidazoline decarboxylase (prhoxnb) CSB-YP375938DIL
CSB-EP375938DIL
CSB-BP375938DIL
CSB-MP375938DIL
CSB-EP375938DIL-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Danio rerio RNA methyltransferase-like protein 1B (rnmtl1b) CSB-YP375939DIL
CSB-EP375939DIL
CSB-BP375939DIL
CSB-MP375939DIL
CSB-EP375939DIL-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Xenopus laevis Centrosomal protein kizuna (plk1s1), partial CSB-YP375940XBE
CSB-EP375940XBE
CSB-BP375940XBE
CSB-MP375940XBE
CSB-EP375940XBE-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Xenopus laevis Transmembrane protein 214-B (tmem214-b), partial CSB-YP375941XBE1
CSB-EP375941XBE1
CSB-BP375941XBE1
CSB-MP375941XBE1
CSB-EP375941XBE1-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Xenopus laevis UPF0595 protein C22orf40 homolog CSB-YP375942XBE
CSB-EP375942XBE
CSB-BP375942XBE
CSB-MP375942XBE
CSB-EP375942XBE-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Xenopus laevis C-Maf-inducing protein (cmip), partial CSB-YP375943XBE
CSB-EP375943XBE
CSB-BP375943XBE
CSB-MP375943XBE
CSB-EP375943XBE-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Human Serine protease 38 (PRSS38) CSB-YP375944HU
CSB-EP375944HU
CSB-BP375944HU
CSB-MP375944HU
CSB-EP375944HU-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Oryza sativa subsp. japonica 1,2-dihydroxy-3-keto-5-methylthiopentene dioxygenase 1 (ARD1) CSB-YP375945OFG
CSB-EP375945OFG
CSB-BP375945OFG
CSB-MP375945OFG
CSB-EP375945OFG-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Arabidopsis thaliana Alcohol dehydrogenase-like 3 (At1g32780) CSB-YP375946DOA
CSB-EP375946DOA
CSB-BP375946DOA
CSB-MP375946DOA
CSB-EP375946DOA-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Mycobacterium tuberculosis UPF0060 membrane protein TBFG_12657 (TBFG_12657), partial CSB-YP375947MOO1
CSB-EP375947MOO1
CSB-BP375947MOO1
CSB-MP375947MOO1
CSB-EP375947MOO1-B
20μg/100μg/1mg(1mg*1 or 500ug*2)
Recombinant Borrelia turicatae 30S ribosomal protein S6 (rpsF) CSB-YP375948BPC
CSB-EP375948BPC
CSB-BP375948BPC
CSB-MP375948BPC
CSB-EP375948BPC-B
20μg/100μg/1mg(1mg*1 or 500ug*2)

有用資源

什么是重組蛋白?

重組蛋白是一種可操縱的蛋白質(zhì)形式,可以通過多種方式產(chǎn)生大量蛋白質(zhì)、修改基因序列和制造有用的商業(yè)產(chǎn)品。重組蛋白的技術(shù)資源在重組蛋白的開發(fā)過程中,除了表達(dá)系統(tǒng)之外,還面臨著一系列令人困惑的選擇,如表達(dá)載體的選擇、表達(dá)蛋白的長度(全長或部分)、是否帶標(biāo)簽等。在生產(chǎn)重組蛋白時(shí),你必須做出很多決定。如果你選擇的明智,你將獲得高質(zhì)量的重組蛋白,后續(xù)的實(shí)驗(yàn)更有可能成功。但是如果你做了錯(cuò)誤的決定,你可能得不到你所需要的重組蛋白或者重組蛋白的質(zhì)量和純度不符合要求。在這里,來自CUSABIO的蛋白表達(dá)工程師根據(jù)他們開發(fā)重組蛋白的經(jīng)驗(yàn)總結(jié)出了幾個(gè)有用的提示,可以幫助你做出明智的決策。

第一條:重組蛋白的生產(chǎn),在這篇文章中,我們旨在闡明重組蛋白的定義以及如何生產(chǎn)重組蛋白。

第二條:如何選擇合適的表達(dá)載體?

表達(dá)載體是一種DNA分子,它攜帶特定的基因進(jìn)入宿主細(xì)胞,并利用細(xì)胞的蛋白質(zhì)合成機(jī)制來產(chǎn)生由該基因編碼的蛋白質(zhì)。表達(dá)載體可使外源基因在宿主細(xì)胞中高效表達(dá),經(jīng)過多年的發(fā)展,表達(dá)載體已成為一種成熟而受歡迎的生物技術(shù)。在重組蛋白生產(chǎn)過程中是一種基本成分。正如標(biāo)題所示,本文主要總結(jié)了幾個(gè)有用的技巧來選擇合適的表達(dá)載體。

第三條:如何表達(dá)具有生物活性的蛋白質(zhì)?

根據(jù)重組蛋白的不同應(yīng)用,對(duì)其生物活性有不同的要求。但是我們?nèi)绾未_保蛋白質(zhì)的產(chǎn)生具有生物活性呢?本文將圍繞這個(gè)主題,并提供一些解決方案。除了以上文章,我們還收集了一些重組蛋白的常見問題。您可以單擊以下鏈接查看。http://m.cstxtech.com/technology-91.html。此外,我們還為我們的客戶提供重組蛋白表達(dá)服務(wù),您可以點(diǎn)擊這里獲取更多信息。注:如果您對(duì)CUSABIO的蛋白質(zhì)有任何疑問,涉及到蛋白質(zhì)的價(jià)格、交貨、質(zhì)量等,您可以點(diǎn)擊橙色按鈕為我們?cè)诰€留言。

引用資料

Recombinant Severe acute respiratory syndrome coronavirus 2 RNA-dependent RNA polymerase(NSP12) cited in "SARS-CoV-2 hijacks cellular kinase CDK2 to promote viral RNA synthesis". Signal transduction and targeted therapy, 2023

Recombinant Mouse Mixed lineage kinase domain-like protein(Mlkl) cited in "OASL phase condensation induces amyloid-like fibrillation of RIPK3 to promote virus-induced necroptosis". Nature cell biology, 2023

Recombinant Mouse Proto-oncogene c-Fos(Fos) cited in "Dihydroartemisinin imposes positive and negative regulation on Treg and plasma cells via direct interaction and activation of c-Fos". Communications biology, 2023

Recombinant Human Keratin, type I cytoskeletal 18(KRT18) cited in "Calcitonin gene-related peptide ameliorates sepsis-induced intestinal injury by suppressing NLRP3 inflammasome activation". International immunopharmacology, 2023

Recombinant Human Protein Wnt-5a (WNT5A) cited in "ATBF1 is a potential diagnostic marker of histological grade and functions via WNT5A in breast cancer". BMC Cancer, 2022

Read More >>